This Biosimulation market report covers market characteristics, size & growth, segmentation, regional & country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
The biosimulation market size has grown rapidly in recent years. It will grow from $4.47 billion in 2024 to $5.02 billion in 2025 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to growing complexity of diseases, rise of in silico trials, drug development cost reduction, growing complexity of diseases, rising prevalence of chronic diseases.
The biosimulation market size is expected to see rapid growth in the next few years. It will grow to $9.65 billion in 2029 at a compound annual growth rate (CAGR) of 17.8%. The growth in the forecast period can be attributed to biosimulation in rare disease research, focus on pharmacodynamics modeling, patient stratification in clinical trials, rapid growth in biopharmaceuticals, biosimulation for drug repurposing, demand for safer and more efficacious drugs. Major trends in the forecast period include digital r&d strategies, technological advancements in simulation software, biosimulation for biomarker identification, optimization of clinical trial design, digital biomarkers and endpoints, continuous advancements in computational biology.
The rise in global healthcare expenditure is expected to bolster the biosimulation market during the forecast period. Increased healthcare spending is anticipated to lead to higher investments in drug development, thereby boosting the revenue generated from biosimulation solutions. Biosimulation software is increasingly being utilized in drug development to simulate diseases. This technology enables virtual clinical trials for new pharmaceutical drugs by using computers to run disease simulations. For example, in July 2024, the American Medical Association, a US-based organization, reported that U.S. healthcare spending increased by 4.1% in 2022, reaching $4.5 trillion, or $13,493 per person. Therefore, the surge in healthcare expenditure is driving the growth of the biosimulation market.
The rising prevalence of chronic diseases is expected to propel the growth of the biosimulation market going forward. Chronic diseases are medical conditions that persist over an extended period of time, often for a person's lifetime. Biosimulation plays a crucial role in understanding the complex mechanisms underlying chronic diseases, aiding in drug development and personalized treatment strategies. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million fatalities, constituting 74% of the total deaths attributed to non-communicable diseases (NCDs) or chronic conditions worldwide each year. These fatalities encompassed 17. 9 million deaths due to cardiovascular diseases, 9. 3 million deaths related to cancer, 4. 1 million deaths associated with chronic respiratory diseases, and 2. 0 million deaths from diabetes. Therefore, the rising prevalence of chronic diseases is driving the growth of the biosimulation market.
Product innovation is becoming a key trend in the biosimulation market, with several companies focusing on developing new and advanced solutions. For example, in June 2023, Certara, Inc., a Pennsylvania-based company that accelerates drug development using proprietary biosimulation software, technology, and services, launched its new Phoenix Biosimulation Software. This software enhances pharmacokinetic (PK) and pharmacodynamic (PD) modeling, improving the efficiency of drug development while reducing costs. It achieves this through streamlined workflows and integrated data analysis tools, offering a more efficient approach to traditional drug discovery and development.
Major companies operating in the biosimulation market are focusing on cloud-based biosimulation to gain a competitive edge in the market. Cloud-based biosimulation software enables researchers to model and analyze complex biological processes remotely, facilitating collaboration and scalability in life sciences. For instance, in October 2023, Optibrium, a UK-based developer of software solutions for small molecule design, optimization, and data analysis, launched a cloud-based version of its drug discovery platform, StarDrop. The updated version maintains the full range of features and user engagement found in the desktop application. Additionally, it enhances accessibility and reduces the overall cost of ownership for clients. StarDrop, now cloud-based, is accessible from any internet-connected device, offering users a flexible way to utilize the software.
In September 2022, Cadence Design Systems Inc., a US-based computer software company acquired OpenEye Scientific Software for an undisclosed amount. With this acquisition Cadence Design Systems, Inc. is focusing on enhancing its capabilities in the field of computational molecular modeling and simulation, particularly within the realm of drug discovery and design. OpenEye Scientific Software is a US-based software company providing bio simulations software tools.
Major companies operating in the biosimulation market include Certara Inc., Dassault Systèmes SE, Schrödinger Inc., Simulations Plus Inc., Rhenovia Pharma SAS, Insilico Biotechnology AG, Genedata AG, Entelos Inc., Physiomics plc, Rosa & Co. LLC., In Silico Biosciences Inc., INOSIM Software GmbH, LeadInvent Technologies Limited, Nuventra Pharma Sciences Inc., Archimedes Inc., VeriSIM Life Inc., Compugen Inc., Leadscope Inc., Pharmaceutical Product Development LLC, Advanced Chemistry Development Inc., Chemical Computing Group Inc., Immunetrics and PPD Inc., Instem India Private Limited, Evidera Inc., Biomodels LLC, PhysioStim SA, Lhasa Limited, SimBioSys Inc., Cadence Design Systems Inc., Allucent Inc.
Biosimulation is a mathematical simulation process that uses computers to replicate biological processes and systems. The aim of biosimulation is a model-based prediction of the dynamics and behavior of biological systems.
The main types of products in the biosimulation market are software and services. The biosimulation software provides software for molecular modelling and simulation, pharmacokinetic/pharmacodynamic (PK/PD) modelling and simulation, toxicity prediction software, physiologically based pharmacokinetic modeling, and simulation (PBPK) modelling and simulation, trial design software, and others. It is used in drug development, drug discovery, and others and implemented in various verticals such as pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory authorities, academic research institutions, others.
The biosimulation market research report is one of a series of new reports that provides biosimulation market statistics, including biosimulation industry global market size, regional shares, competitors with a biosimulation market share, detailed biosimulation market segments, market trends and opportunities, and any further data you may need to thrive in the biosimulation industry. This biosimulation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
North America was the largest region in the biosimulation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimulation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the biosimulation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
The biostimulation market includes revenues earned by entities by providing stimulation technology that provide simulations of biological processes and predict the behavior of biological systems to enhance the research and development (R&D) process. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
The biosimulation market size has grown rapidly in recent years. It will grow from $4.47 billion in 2024 to $5.02 billion in 2025 at a compound annual growth rate (CAGR) of 12.2%. The growth in the historic period can be attributed to growing complexity of diseases, rise of in silico trials, drug development cost reduction, growing complexity of diseases, rising prevalence of chronic diseases.
The biosimulation market size is expected to see rapid growth in the next few years. It will grow to $9.65 billion in 2029 at a compound annual growth rate (CAGR) of 17.8%. The growth in the forecast period can be attributed to biosimulation in rare disease research, focus on pharmacodynamics modeling, patient stratification in clinical trials, rapid growth in biopharmaceuticals, biosimulation for drug repurposing, demand for safer and more efficacious drugs. Major trends in the forecast period include digital r&d strategies, technological advancements in simulation software, biosimulation for biomarker identification, optimization of clinical trial design, digital biomarkers and endpoints, continuous advancements in computational biology.
The rise in global healthcare expenditure is expected to bolster the biosimulation market during the forecast period. Increased healthcare spending is anticipated to lead to higher investments in drug development, thereby boosting the revenue generated from biosimulation solutions. Biosimulation software is increasingly being utilized in drug development to simulate diseases. This technology enables virtual clinical trials for new pharmaceutical drugs by using computers to run disease simulations. For example, in July 2024, the American Medical Association, a US-based organization, reported that U.S. healthcare spending increased by 4.1% in 2022, reaching $4.5 trillion, or $13,493 per person. Therefore, the surge in healthcare expenditure is driving the growth of the biosimulation market.
The rising prevalence of chronic diseases is expected to propel the growth of the biosimulation market going forward. Chronic diseases are medical conditions that persist over an extended period of time, often for a person's lifetime. Biosimulation plays a crucial role in understanding the complex mechanisms underlying chronic diseases, aiding in drug development and personalized treatment strategies. For instance, in September 2023, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million fatalities, constituting 74% of the total deaths attributed to non-communicable diseases (NCDs) or chronic conditions worldwide each year. These fatalities encompassed 17. 9 million deaths due to cardiovascular diseases, 9. 3 million deaths related to cancer, 4. 1 million deaths associated with chronic respiratory diseases, and 2. 0 million deaths from diabetes. Therefore, the rising prevalence of chronic diseases is driving the growth of the biosimulation market.
Product innovation is becoming a key trend in the biosimulation market, with several companies focusing on developing new and advanced solutions. For example, in June 2023, Certara, Inc., a Pennsylvania-based company that accelerates drug development using proprietary biosimulation software, technology, and services, launched its new Phoenix Biosimulation Software. This software enhances pharmacokinetic (PK) and pharmacodynamic (PD) modeling, improving the efficiency of drug development while reducing costs. It achieves this through streamlined workflows and integrated data analysis tools, offering a more efficient approach to traditional drug discovery and development.
Major companies operating in the biosimulation market are focusing on cloud-based biosimulation to gain a competitive edge in the market. Cloud-based biosimulation software enables researchers to model and analyze complex biological processes remotely, facilitating collaboration and scalability in life sciences. For instance, in October 2023, Optibrium, a UK-based developer of software solutions for small molecule design, optimization, and data analysis, launched a cloud-based version of its drug discovery platform, StarDrop. The updated version maintains the full range of features and user engagement found in the desktop application. Additionally, it enhances accessibility and reduces the overall cost of ownership for clients. StarDrop, now cloud-based, is accessible from any internet-connected device, offering users a flexible way to utilize the software.
In September 2022, Cadence Design Systems Inc., a US-based computer software company acquired OpenEye Scientific Software for an undisclosed amount. With this acquisition Cadence Design Systems, Inc. is focusing on enhancing its capabilities in the field of computational molecular modeling and simulation, particularly within the realm of drug discovery and design. OpenEye Scientific Software is a US-based software company providing bio simulations software tools.
Major companies operating in the biosimulation market include Certara Inc., Dassault Systèmes SE, Schrödinger Inc., Simulations Plus Inc., Rhenovia Pharma SAS, Insilico Biotechnology AG, Genedata AG, Entelos Inc., Physiomics plc, Rosa & Co. LLC., In Silico Biosciences Inc., INOSIM Software GmbH, LeadInvent Technologies Limited, Nuventra Pharma Sciences Inc., Archimedes Inc., VeriSIM Life Inc., Compugen Inc., Leadscope Inc., Pharmaceutical Product Development LLC, Advanced Chemistry Development Inc., Chemical Computing Group Inc., Immunetrics and PPD Inc., Instem India Private Limited, Evidera Inc., Biomodels LLC, PhysioStim SA, Lhasa Limited, SimBioSys Inc., Cadence Design Systems Inc., Allucent Inc.
Biosimulation is a mathematical simulation process that uses computers to replicate biological processes and systems. The aim of biosimulation is a model-based prediction of the dynamics and behavior of biological systems.
The main types of products in the biosimulation market are software and services. The biosimulation software provides software for molecular modelling and simulation, pharmacokinetic/pharmacodynamic (PK/PD) modelling and simulation, toxicity prediction software, physiologically based pharmacokinetic modeling, and simulation (PBPK) modelling and simulation, trial design software, and others. It is used in drug development, drug discovery, and others and implemented in various verticals such as pharmaceutical and biotechnology companies, contract research organizations (CROs), regulatory authorities, academic research institutions, others.
The biosimulation market research report is one of a series of new reports that provides biosimulation market statistics, including biosimulation industry global market size, regional shares, competitors with a biosimulation market share, detailed biosimulation market segments, market trends and opportunities, and any further data you may need to thrive in the biosimulation industry. This biosimulation market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
North America was the largest region in the biosimulation market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the biosimulation market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the biosimulation market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain.
The biostimulation market includes revenues earned by entities by providing stimulation technology that provide simulations of biological processes and predict the behavior of biological systems to enhance the research and development (R&D) process. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Biosimulation Market Characteristics3. Biosimulation Market Trends and Strategies4. Biosimulation Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics and Covid and Recovery on the Market32. Global Biosimulation Market Competitive Benchmarking and Dashboard33. Key Mergers and Acquisitions in the Biosimulation Market34. Recent Developments in the Biosimulation Market
5. Global Biosimulation Growth Analysis and Strategic Analysis Framework
6. Biosimulation Market Segmentation
7. Biosimulation Market Regional and Country Analysis
8. Asia-Pacific Biosimulation Market
9. China Biosimulation Market
10. India Biosimulation Market
11. Japan Biosimulation Market
12. Australia Biosimulation Market
13. Indonesia Biosimulation Market
14. South Korea Biosimulation Market
15. Western Europe Biosimulation Market
16. UK Biosimulation Market
17. Germany Biosimulation Market
18. France Biosimulation Market
19. Italy Biosimulation Market
20. Spain Biosimulation Market
21. Eastern Europe Biosimulation Market
22. Russia Biosimulation Market
23. North America Biosimulation Market
24. USA Biosimulation Market
25. Canada Biosimulation Market
26. South America Biosimulation Market
27. Brazil Biosimulation Market
28. Middle East Biosimulation Market
29. Africa Biosimulation Market
30. Biosimulation Market Competitive Landscape and Company Profiles
31. Biosimulation Market Other Major and Innovative Companies
35. Biosimulation Market High Potential Countries, Segments and Strategies
36. Appendix
Executive Summary
Biosimulation Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on biosimulation market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for biosimulation? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The biosimulation market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) By Product: Software; Services2) By Application: Drug Development; Drug Discovery; Other Applications
3) By End User: Pharmaceutical And Biotechnology Companies; Contract Research Organizations (CROs); Regulatory Authorities; Academic Research Institutions; Other End Users
Subsegments:
1) By Software: Pharmacokinetics (PK) Simulation Software; Pharmacodynamics (PD) Simulation Software; Toxicology Simulation Software; Disease Modeling Software; Integrated Biosimulation Platforms2) By Services: Consulting Services; Model Development Services; Data Analysis And Interpretation Services; Training And Support Services; Custom Simulation Services.
Key Companies Mentioned: Certara Inc.; Dassault Systèmes SE; Schrödinger Inc.; Simulations Plus Inc.; Rhenovia Pharma SAS
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
The major companies featured in this Biosimulation market report include:- Certara Inc.
- Dassault Systèmes SE
- Schrödinger Inc.
- Simulations Plus Inc.
- Rhenovia Pharma SAS
- Insilico Biotechnology AG
- Genedata AG
- Entelos Inc.
- Physiomics plc
- Rosa & Co. LLC.
- In Silico Biosciences Inc.
- INOSIM Software GmbH
- LeadInvent Technologies Limited
- Nuventra Pharma Sciences Inc.
- Archimedes Inc.
- VeriSIM Life Inc.
- Compugen Inc.
- Leadscope Inc.
- Pharmaceutical Product Development LLC
- Advanced Chemistry Development Inc.
- Chemical Computing Group Inc.
- Immunetrics and PPD Inc.
- Instem India Private Limited
- Evidera Inc.
- Biomodels LLC
- PhysioStim SA
- Lhasa Limited
- SimBioSys Inc.
- Cadence Design Systems Inc.
- Allucent Inc.
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | January 2025 |
| Forecast Period | 2025 - 2029 |
| Estimated Market Value ( USD | $ 5.02 Billion |
| Forecasted Market Value ( USD | $ 9.65 Billion |
| Compound Annual Growth Rate | 17.8% |
| Regions Covered | Global |
| No. of Companies Mentioned | 31 |
